Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro-Reference-Cited by-同舟云学术

Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro

Published:2002-09 Issue:9 Volume:46 Page:3057-3060
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Delaney William E.¹,Edwards Ros¹,Colledge Danni¹,Shaw Tim¹,Furman Phil²,Painter George²,Locarnini Stephen¹

Affiliation:

1. Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia

2. Triangle Pharmaceuticals, Durham, North Carolina 27707

Abstract

ABSTRACT The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type HBV with 50% inhibitory concentrations of 21.2 ± 9.5 and 2.40 ± 0.92 μM, respectively, compared to 0.064 ± 0.020 μM lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.9.3057-3060.2002

Reference31 articles.

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, L. D. Condreay, et al. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology27:1670-1677.

2. Aye, T. T., A. Bartholomeusz, T. Shaw, S. Bowden, A. Breschkin, J. McMillan, P. Angus, and S. Locarnini. 1998. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol.26:1148-1153.

3. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzendahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet349:20-22.

4. Colacino, J. M., and K. A. Staschke. 1998. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog. Drug Res.50:259-322.

5. In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Colchicine-mediated selective autophagic degradation of HBV core proteins inhibits HBV replication and HBV-related hepatocellular carcinoma progression;Cell Death Discovery;2024-08-06

2. Biophysics-Guided Lead Discovery of HBV Capsid Assembly Modifiers;ACS Infectious Diseases;2024-04-02

3. A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression;Antiviral Research;2024-01

4. Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure;Global Health & Medicine;2023-08-31

5. Targeting the HIV-1 and HBV Capsids, an EnCore;Viruses;2023-03-31